uploads/2019/05/syringe-1884779_1280.jpg

What Analysts Are Recommending for Novavax after Q1 Results

By

Updated

Stock price movements

Novavax (NVAX) reported first-quarter results on May 2. The company reported revenues of $3.98 billion in the first quarter, a YoY decline of 58.75% and $0.62 million short of the consensus revenue estimate. In the first quarter, the company reported a net loss of $43.22 million, a YoY improvement of 6.76%. In the first quarter, Novavax reported diluted EPS of -$0.11, a YoY improvement of 21.43%.

After the results, Novavax closed at $0.53 on May 2, 3.92% higher than the previous close. On May 3, the company closed at $0.47, 3.29% lower than its 52-week low of $0.49, and 81.67% lower than its 52-week high of $2.58. The company’s market capitalization is $228.63 and PS (price-to-sales) and PC (price-to-cash) ratios were 6.67x and 2.48x, respectively. With a market capitalization lower than $300 million, Novavax is a micro-cap stock and can pose higher risks to retail investors as compared to the broader market or even large-cap stocks.

Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Novavax’s 14-day RSI (relative strength index) is currently 37.18. The number of outstanding shares for the company is 469.50 million, while the short float ratio is 20.68%.

Based on its share price on May 3, Novavax has reported returns of -3.57%, -20.47%, -79.44%, -72.18%, -70.44%, and -74.30%, in the previous week, previous month, previous quarter, previous half year, previous year, and YTD, respectively.

Article continues below advertisement

Analysts’ recommendations and target price

Wall Street analysts expect an upside potential of 208.73% for Novavax based on the company’s closing price on May 3. Analysts have slashed the company’s 12-month consensus target price from $4.38 in February to $2.13 in March to $1.46 in April and May.

Out of eight analysts covering Novavax, three analysts recommend a “strong buy,” two recommend a “buy,” two recommend a “hold,” and one analyst recommends a “sell.” The consensus recommendation for the company is a “buy.”

Advertisement

More From Market Realist